GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (WBO:ABBV) » Definitions » Cyclically Adjusted Revenue per Share

AbbVie (WBO:ABBV) Cyclically Adjusted Revenue per Share : €24.39 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is AbbVie Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

AbbVie's adjusted revenue per share for the three months ended in Mar. 2024 was €6.388. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €24.39 for the trailing ten years ended in Mar. 2024.

During the past 12 months, AbbVie's average Cyclically Adjusted Revenue Growth Rate was 7.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 14.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of AbbVie was 14.30% per year. The lowest was 14.30% per year. And the median was 14.30% per year.

As of today (2024-05-14), AbbVie's current stock price is €148.62. AbbVie's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €24.39. AbbVie's Cyclically Adjusted PS Ratio of today is 6.09.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AbbVie was 8.05. The lowest was 4.91. And the median was 6.12.


AbbVie Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for AbbVie's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AbbVie Cyclically Adjusted Revenue per Share Chart

AbbVie Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 13.95 18.17 22.44 23.56

AbbVie Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.38 23.11 24.70 23.56 24.39

Competitive Comparison of AbbVie's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, AbbVie's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AbbVie's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AbbVie's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where AbbVie's Cyclically Adjusted PS Ratio falls into.



AbbVie Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AbbVie's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=6.388/129.4194*129.4194
=6.388

Current CPI (Mar. 2024) = 129.4194.

AbbVie Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 2.255 100.560 2.902
201409 2.419 100.428 3.117
201412 2.741 99.070 3.581
201503 2.896 99.621 3.762
201506 2.987 100.684 3.839
201509 3.183 100.392 4.103
201512 3.576 99.792 4.638
201603 3.292 100.470 4.241
201606 3.519 101.688 4.479
201609 3.494 101.861 4.439
201612 3.965 101.863 5.038
201703 3.813 102.862 4.797
201706 3.863 103.349 4.837
201709 3.661 104.136 4.550
201712 4.072 104.011 5.067
201803 4.032 105.290 4.956
201806 4.508 106.317 5.488
201809 4.659 106.507 5.661
201812 4.863 105.998 5.938
201903 4.671 107.251 5.637
201906 4.923 108.070 5.896
201909 5.191 108.329 6.202
201912 5.268 108.420 6.288
202003 5.256 108.902 6.246
202006 5.621 108.767 6.688
202009 6.175 109.815 7.277
202012 6.396 109.897 7.532
202103 6.157 111.754 7.130
202106 6.524 114.631 7.366
202109 6.860 115.734 7.671
202112 7.401 117.630 8.143
202203 6.914 121.301 7.377
202206 7.768 125.017 8.042
202209 8.423 125.227 8.705
202212 8.015 125.222 8.284
202303 6.429 127.348 6.534
202306 7.226 128.729 7.265
202309 7.368 129.860 7.343
202312 7.384 129.419 7.384
202403 6.388 129.419 6.388

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


AbbVie  (WBO:ABBV) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

AbbVie's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=148.62/24.39
=6.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of AbbVie was 8.05. The lowest was 4.91. And the median was 6.12.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


AbbVie Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of AbbVie's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


AbbVie (WBO:ABBV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AbbVie Inc (WBO:ABBV) » Definitions » Cyclically Adjusted Revenue per Share
Address
1 North Waukegan Road, North Chicago, IL, USA, 60064-6400
AbbVie is a pharmaceutical firm with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

AbbVie (WBO:ABBV) Headlines

From GuruFocus

Q4 2022 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc at JPMorgan Healthcare Conference Transcript

By GuruFocus Research 01-22-2024

Q3 2023 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024

Abbvie Inc will Acquire ImmunoGen Inc M&A Call Transcript

By GuruFocus Research 01-22-2024

Q3 2021 Abbvie Inc Earnings Call Transcript

By GuruFocus Research 01-22-2024